Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
|
SE |
|
B
|
BridgeBio Pharma Inc
XBER:2CL
|
US |
|
Novonix Ltd
ASX:NVX
|
AU |
|
A
|
AGC Inc
DUS:SHJ
|
JP |
|
Namura Shipbuilding Co Ltd
OTC:NMRSF
|
JP |
|
S
|
Sedlmayr Grund und Immobilien AG
XMUN:SPB
|
DE |
Wall St Price Targets
B6E Price Targets Summary
Swedish Orphan Biovitrum AB (publ)
According to Wall Street analysts, the average 1-year price target for B6E is 42.81 EUR with a low forecast of 28.01 EUR and a high forecast of 52.01 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is B6E's stock price target?
Price Target
42.81
EUR
According to Wall Street analysts, the average 1-year price target for B6E is 42.81 EUR with a low forecast of 28.01 EUR and a high forecast of 52.01 EUR.
What is the Revenue forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 23%. The projected CAGR for the next 8 years is 9%.
What is the Gross Profit forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 27%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
600%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 600%.
What is the Net Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
43%
The compound annual growth rate for Net Income over the next 8 years is 43%.
